Technology
Health
Pharmaceutical
SCYNEXIS
$1.489876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
$0.00 (0.00%) Today
-$0.09 (-5.73%) After Hours
Why Robinhood?
You can buy or sell SCYNEXIS and other stocks, options, ETFs, and crypto commission-free!
About
SCYNEXIS, Inc. Common Stock, also called SCYNEXIS, is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. Read More The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Employees
24
Headquarters
Jersey City, New Jersey
Founded
1999
Market Cap
75.32M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
665.59K
High Today
$1.60
Low Today
$1.51
Open Price
$1.56
Volume
192.89K
52 Week High
$2.15
52 Week Low
$0.35
Collections
Technology
Health
Pharmaceutical
2014 IPO
US
North America
News
Markets InsiderMar 14
SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update
JERSEY CITY, N.J., March 14, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the year ended December 31, 2018, and provided an update on recent operational and clinical developments. "We ended 2018 having accomplished meaningful progress across our ibrexafungerp clinical development programs, including positive results from our Phase 2b DOVE study ev...
PR NewswireMar 7
SCYNEXIS is Retiring Existing Term Loan Through a Lower-Interest and Longer-Term Convertible Note
JERSEY CITY, N.J., March 7, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the sale of a $16.0 million aggregate principal amount of 6.0% convertible senior note due 2025 (the "note"). The note was sold in a private offering to Puissance Capital Management pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The sale of the note i...
PR NewswireFeb 28
SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019
JERSEY CITY, N.J., Feb. 28, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present new in vivo data supporting the potential use of oral ibrexafungerp (formerly SCY-078) for the prevention and treatment of Pneumocystis pneumonia (PCP), a significant risk for immunocompromised patients. The presentation will take place on March 18th at 4PM GMT at Sup...
Price Paid on Robinhood
10% Higher
Right Now
52 Week Low
$0.35
Average Price Paid
$1.34
52 Week High
$2.15
Earnings
-$0.34
-$0.22
-$0.11
$0.01
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.14 per share
Actual
-$0.10 per share